Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
128
days
Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment
AuthorsJingheng Wu; Miaomiao Li; Shuai Wang
Affiliations1. Department of Functional Neurosurgery of Shengjing Hospital, China Medical University, Shenyang, China; 2. Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin, China; 3. Tianjin Key Laboratory of Cerebral Blood Flow Reconstruction and Head and Neck Tumor New Technology Translation, Tianjin Neurosurgical Institute, Tianjin Huanhu Hospital, Tianjin, China; 4. Liaoning Clinical Medical Research Center in Nervous System Disease, Shenyang, China; 5. Shenyang, China
57
days
How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis
AuthorsCassandra Weng-Yan Lai; Suzanne A. M. Wenker; Paul W. Groundwater; Justin Beardsley; Gaurav Sutrave; Ricky Hao Chen; Anne-Grete Märtson; Jan-Willem C. Alffenaar
Affiliations1. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; 2. Faculty of Science, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands; 3. Sydney Institute for Infectious Diseases, University of Sydney, Sydney, Australia; 4. Department of Infectious Diseases, Westmead Hospital, Westmead, Australia; 5. Sydney Medical School-Westmead, University of Sydney, Sydney, Australia; 6. Department of Hematology, Westmead Hospital, Westmead, Australia; 7. Department of Pharmacy, Westmead Hospital, Westmead, Australia
76
days
Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma
AuthorsMahipal Sinnollareddy; Kinjal Sanghavi; Leonid Gibiansky; Tommy Li; Matthew Putnins; Mohamed-Eslam F. Mohamed; Poliana Patah; Elena Favaro; Manish Gupta; Apurvasena Parikh; Steven Xu
Affiliations1. Clinical Pharmacology, AbbVie Inc., North Chicago, USA; 2. Clinical Pharmacology, AbbVie Inc., Irvine, USA; 3. Genmab, Plainsboro, USA; 4. QuantPharm LLC, North Potomac, USA; 5. Genmab, Copenhagen, Denmark; 6. Clinical Pharmacology, AbbVie Inc., South San Francisco, USA
162
days
Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate
AuthorsHylke Waalewijn; Lisanne A. H. Bevers; Linda L. Lewis; Margaret D. Louey; Sonoko Kawakatsu; Yanan Zheng; Carlo Giaquinto; Alessandra Nardone; David M. Burger; Rob ter Heine; Angela Colbers; Elin M. Svensson
Affiliations1. Department of Pharmacy, Pharmacology and Toxicology, Radboud Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands; 2. Product Development, Quality, Costing and Regulatory Affairs, Clinton Health Access Initiative, Boston, USA; 3. Gilead Sciences, Inc., Foster City, USA; 4. Fondazione Penta ETS, Padova, Italy; 5. Department of Pharmacy, Uppsala University, Uppsala, Sweden
109
days
Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease
AuthorsSanjana Parikh; Kei Irie; Ryota Tanaka; Takanobu Nadai; Phillip Minar; Tomoyuki Mizuno
Affiliations1. Division of Translational and Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 2. Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, USA; 3. Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan; 4. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 5. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, USA
130
days
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation
AuthorsJen-Hao Wu; Francisco Bautista; Erica Brivio; Marieke Willemse; Karey Kowalski; Brian Jermain; May Garrett; Andrew Bukowinski; Carmelo Rizzari; Jessica Pollard; Laura Murillo-Sanjuán; Matthew Kutny; Sara Zarnegar-Lumley; Michele Redell; Stacy Cooper; Yves Bertrand; Arnaud Petit; Julie Krystal; Markus Metzler; Donna Lancaster; Jean-Pierre Bourquin; Jayashree Motwani; Inge M. van der Sluis; Franco Locatelli; Michael E. Roth; Nobuko Hijiya; C. Michel Zwaan; Alwin D. R. Huitema
Affiliations1. Department of Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands; 2. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; 3. Pfizer Inc, La Jolla, USA; 4. UPMC Children’s Hospital of Pittsburgh, Pittsburgh, USA; 5. Pediatric Hematology and Oncology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy; 6. Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, USA; 7. Hospital Universitari Vall d’Hebron, Barcelona, Spain; 8. Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, USA; 9. Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA; 10. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, USA; 11. Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, USA; 12. CHU Lyon/Hospices Civils de Lyon, Lyon, France; 13. Armand Trousseau Hospital, APHP, Sorbonne Université, Paris, France; 14. The Steven and Alexandra Cohen Children’s Medical Center of New York, New York, USA; 15. Universitätsklinikum Erlangen, Erlangen, Germany; 16. The Royal Marsden NHS Foundation Trust, London, UK; 17. University Children’s Hospital, Zürich, Switzerland; 18. Birmingham Children’s Hospital, Birmingham, UK; 19. IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy; 20. University of Texas M. D. Anderson Cancer Center, Houston, USA; 21. Columbia University Irving Medical Center, New York, USA; 22. Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 23. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
145
days
The Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants
AuthorsErik Hahn; Joseph Piscitelli; Dustin Huynh; Renae Chavira; Lance Wollenberg; Micaela B. Reddy
Affiliations1. Pfizer Inc., San Diego, USA; 2. Pfizer Inc., New York, USA
166
days
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
AuthorsAlexander Nasr; Tomoyuki Mizuno; Kei Irie; Jonathan R. Dillman; Kimberly Jackson; Kimberly Lynch; Alexa Horrell; Thomas Aviles; Kelly Chun; Jane Yang; Brendan Boyle; Jeffrey S. Hyams; Joshua Noe; Lee. A. Denson; Phillip Minar
Affiliations1. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 2. University of Cincinnati College of Medicine, Cincinnati, USA; 3. Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 4. Department of Radiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 5. Esoterix, LabCorp Specialty Lab, Calabasas, USA; 6. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Nationwide Children’s Hospital, Columbus, USA; 7. Division of Digestive Diseases and Nutrition, Connecticut Children’s Medical Center, Hartford, USA; 8. Division of Pediatric Gastroenterology, Medical College of Wisconsin, Milwaukee, USA
107
days
Low Tacrolimus C 0 /Dose Ratio is Associated with Higher C max and AUC Despite Similar Pre-dose Concentrations
AuthorsAmar D. Levens; Teun van Gelder; Armin Gelinck; Soufian Meziyerh; Aiko P. J. de Vries; Danny van der Helm; Jesse J. Swen; Dirk Jan A. R. Moes
Affiliations1. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; 2. Leiden Transplant Center, Leiden University Medical Center and Leiden University, Leiden, The Netherlands; 3. Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
97
days
A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics
AuthorsRiley M. Randolph; Sara Jubas; Li Gong; Raman Venkataramanan; Dhrita Khatri; Pamala A. Jacobson; David Metz; Daniel J. Crona
Affiliations1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA; 2. Department of Biomedical Data Science, Stanford University, Stanford, USA; 3. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA; 4. Cancer Therapies, Stem Cell Medicine, Murdoch Children’s Research Institute, Parkville, Australia; 5. Department of Paediatrics, The University of Melbourne, Parkville, Australia; 6. Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA; 7. Department of Nephrology, Royal Children’s Hospital, Melbourne, Australia; 8. Department of Paediatrics, Monash University, Melbourne, Australia; 9. Murdoch Children’s Research Institute, Melbourne, Australia; 10. Monash Children’s Hospital, Monash Health, Melbourne, Australia; 11. Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, USA; 12. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days